Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum-Reference-Cited by-同舟云学术

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum

Published:2018-02-12 Issue:8 Volume:20 Page:1230-1239
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Lund Lars H.¹,Claggett Brian²,Liu Jiankang²,Lam Carolyn S.³,Jhund Pardeep S.⁴,Rosano Giuseppe M.⁵,Swedberg Karl⁶,Yusuf Salim⁷,Granger Christopher B.⁸,Pfeffer Marc A.²,McMurray John J.V.⁴,Solomon Scott D.²

Affiliation:

1. Unit of Cardiology, Department of Medicine; Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital; Stockholm Sweden

2. Division of Cardiovascular Medicine; Brigham and Women's Hospital; Boston MA USA

3. National Heart Centre Singapore; Duke-NUS Medical School, and Cardiovascular Research Institute, National University Health System; Singapore

4. BHF Cardiovascular Research Centre; Institute of Cardiovascular and Medical Sciences, University of Glasgow; Glasgow UK

5. Cardiovascular and Cell Sciences Research Institute, St George's University, London, UK; and IRCCS San Raffaele Pisana; Rome Italy

6. Sahlgrenska Academy; University of Gothenburg; Gothenburg Sweden

7. Department of Medicine and Population Health Research Institute; McMaster University and Hamilton Health Sciences; Ontario Canada

8. Duke Clinical Research Institute; Duke University; Durham NC USA

Funder

AstraZeneca

Vetenskapsrådet

Swedish Heart Lung Foundation

Stockholms Läns Landsting

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ejhf.1149/fullpdf

Reference26 articles.

1. Developed with the special contribution of the Heart Failure Association (HFA) of the ESC;Ponikowski;Eur J Heart Fail,2016

2. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%);Lam;Eur J Heart Fail,2014

3. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study;Vedin;Circ Heart Fail,2017

4. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction;Lofman;Eur J Heart Fail,2017

5. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry;Chioncel;Eur J Heart Fail,2017

Cited by 331 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry;European Journal of Heart Failure;2024-09-10

2. Long‐Term Risk of Cardiovascular Death in Patients With Mildly Reduced Ejection Fraction After Acute Myocardial Infarction: A Multicenter, Prospective Registry Study;Journal of the American Heart Association;2024-09-09

3. Insights into the post-translational modifications in heart failure;Ageing Research Reviews;2024-09

4. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis;The Lancet;2024-09

5. Polypharmacy and Guideline-Directed Medical Therapy Initiation Among Adults Hospitalized With Heart Failure;JACC: Advances;2024-09